Fresenius Kabi Releases Lovo Software 2.0

New version allows customization of parameters to support users’ processes

August 10, 2016

Lake Zurich, Ill., August 10, 2016 – Fresenius Kabi announced today the global release of a software update for the Lovo Cell Processing System (www.fresenius-kabi.us/lovo). The development of Lovo Software 2.0 expands the flexibility of the system, allowing users to customize more parameters to better support their unique processes.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

Lovo is a fully automated cell processing system that removes supernatant from target cells and stores them in viable media. Lovo automates the labor-intensive tasks of separation, washing, platelet-depletion, fluid-exchange, and concentration of living cells that are used by academic medical centers and biotechnology companies in their development of cell therapies.

New features added in the Lovo Software 2.0 include:

  • Ability to create and store up to 10 custom protocols
  • Expanded input and output volumes
  • Automated use of 2 wash solutions
  • Pause capability, both pre-configured and on-demand
  • Defined administrator and operator roles

“Since Lovo’s market introduction in 2014, our customers have found it useful for a broad spectrum of applications and cell products. The new features and usability enhancements in Lovo 2.0 are a direct result of our customers’ requests to expand its use even further,” said Daryl Calhoun, vice president of Automated Blood Technologies at Fresenius Kabi. “Cell therapy is a rapidly evolving field, and Fresenius Kabi is committed to delivering enhancements consistent with our customers’ changing needs.”

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.

 

Media Contact
Matt Kuhn
847-550-5751
matt.kuhn@fresenius-kabi.com